Uzay E Emir1,2, Jannie Wijnen3, Olaf E Ansorge4, Evita Wiegers3, Anja van der Kolk5, Alexander Lin6, and Clark Chen7
1School of Health Sciences, Purdue University, West Lafayette, IN, United States, 2Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, United States, 3Radiology, University Medical Centre Utrecht, Utrecht, Netherlands, 4University of Oxford, Oxford, United Kingdom, 5Antoni van Leeuwenhoek Hospital, Netherlands Cancer Center, Amsterdam, Netherlands, 6Brigham and Women’s Hospital / Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States, 7Department of Neurosurgery, University of Minnesota, Minneapolis, MN, United States
1School of Health Sciences, Purdue University, West Lafayette, IN, United States, 2Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, United States, 3Radiology, University Medical Centre Utrecht, Utrecht, Netherlands, 4University of Oxford, Oxford, United Kingdom, 5Antoni van Leeuwenhoek Hospital, Netherlands Cancer Center, Amsterdam, Netherlands, 6Brigham and Women’s Hospital / Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States, 7Department of Neurosurgery, University of Minnesota, Minneapolis, MN, United States
The collection of prospectively acquired UHF MRS spectra from multiple international centres could lead to a widely accepted prognostic precision medicine biomarker detection system for identifying, stratifying, and monitoring IDH1 and IDH2 mutant glioma patients.
Descriptive measures of the predicted IDH status from the visual inspection
Information provided to participants at the beginning of the survey.